Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 4/20 | 0.51 |
| ▸ | EGFR | P00533 | 4/20 | 0.51 |
| ▸ | ABL2 | P42684 | 4/20 | 0.51 |
| ▸ | SRC | P12931 | 9/20 | 0.48 |
| ▸ | LCK | P06239 | 2/20 | 0.48 |
| ▸ | KDR | P35968 | 2/20 | 0.48 |
| ▸ | TEK | Q02763 | 2/20 | 0.48 |
| ▸ | BTK | Q06187 | 2/20 | 0.46 |
| ▸ | HCK | P08631 | 6/20 | 0.45 |
| ▸ | FLT3 | P36888 | 5/20 | 0.45 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.44 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.44 |
| ▸ | PRKCG | P05129 | 1/20 | 0.44 |
| ▸ | PRKCB | P05771 | 1/20 | 0.44 |
| ▸ | PRKCA | P17252 | 1/20 | 0.44 |
| ▸ | PRKCH | P24723 | 1/20 | 0.44 |
| ▸ | PRKCI | P41743 | 1/20 | 0.44 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.44 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.44 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17065604 | 0.88 | BTK (0.59) | ABL1EGFRABL2SRCLCK | |
| SCHEMBL18335352 | 0.84 | BTK (0.65) | ABL1EGFRABL2SRCLCK | |
| SCHEMBL17065745 | 0.84 | BTK (0.51) | ABL1EGFRABL2SRCLCK | |
| SCHEMBL17065606 | 0.82 | BTK (0.53) | ABL1EGFRABL2SRCLCK | |
| SCHEMBL17065602 | 0.82 | BTK (0.53) | ABL1EGFRABL2SRCLCK | |
| SCHEMBL17065599 | 0.80 | BTK (0.63) | ABL1EGFRABL2SRCLCK | |
| SCHEMBL17065600 | 0.80 | BTK (0.63) | ABL1EGFRABL2SRCLCK | |
| SCHEMBL17065587 | 0.80 | BTK (0.48) | ABL1EGFRABL2SRCBTK | |
| SCHEMBL18335280 | 0.80 | BTK (0.48) | ABL1EGFRABL2SRCBTK | |
| SCHEMBL18335324 | 0.79 | BTK (0.52) | ABL1EGFRABL2SRCBTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160376277-A1 | NOVEL HETEROCYCLIC COMPOUNDS | CADILA HEALTHCARE LIMITED (IN) | 2016-12-29 | — | — | US | claimed |
| EP-3102579-A2 | HETEROCYCLIC COMPOUNDS | Cadila Healthcare Limited (IN) | 2016-12-14 | — | — | EP | claimed |
| WO-2015132799-A2 | NOVEL HETEROCYCLIC COMPOUNDS | CADILA HEALTHCARE LIMITED (IN) | 2015-09-11 | — | — | WO | claimed |
| EP-3102579-B1 | HETEROCYCLIC COMPOUNDS | CADILA HEALTHCARE LTD (IN) | 2019-04-10 | — | — | EP | disclosed |
| US-9840509-B2 | Heterocyclic compounds | CADILA HEALTHCARE LIMITED (IN) | 2017-12-12 | — | — | US | disclosed |
| US-9840509-B2 | Heterocyclic compounds | CADILA HEALTHCARE LIMITED (IN) | 2017-12-12 | — | — | US | disclosed |
| US-9840509-B2 | Heterocyclic compounds | CADILA HEALTHCARE LIMITED (IN) | 2017-12-12 | — | — | US | disclosed |
| US-20160376277-A1 | NOVEL HETEROCYCLIC COMPOUNDS | CADILA HEALTHCARE LIMITED (IN) | 2016-12-29 | — | — | US | disclosed |
| US-20160376277-A1 | NOVEL HETEROCYCLIC COMPOUNDS | CADILA HEALTHCARE LIMITED (IN) | 2016-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160376277-A1 | NOVEL HETEROCYCLIC COMPOUNDS | BTK, LYN, SYK | ABL1 5/4885EGFR 425/4885ABL2 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.